
Pre-made Afasevikumab benchmark antibody ( Whole mAb, anti-IL17A/IL17 therapeutic antibody, Anti-CTLA-8/CTLA8A/ILA17 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-012
Pre-Made Afasevikumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Afasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A (IL17A) and interleukin 17F (IL17F). This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-012-1mg | 1mg | 3090 | ||
GMP-Bios-ab-012-10mg | 10mg | 21890 | ||
GMP-Bios-ab-012-100mg | 100mg | 148000 | ||
GMP-Bios-ab-012-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Afasevikumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody |
INN Name | Afasevikumab |
Target | IL17 |
Format | Whole mAb |
Derivation | Human |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-I |
Est. Status | Discontinued |
100% SI Structure | 6ppg:HL:BA |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2015 |
Year Recommended | 2016 |
Companies | NovImmune;Genentech |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Autoimmune disorders;Inflammation |
Development Tech | na |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
